Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study
The purpose of the present proposal was to investigate the predictive properties of markers in exhaled breath to predict an asthma exacerbation. In addition, the reliability of home monitor assessments to measure asthma control will be examined.
Exhaled Breath Condensate
Non-invasive Inflammatory Markers
Volatile Organic Compounds
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study|
- number of exacerbations [ Time Frame: 1 year ] [ Designated as safety issue: No ]increase of asthma symptoms, use of short b2-agonists, drop in FEV1% of maximum personal value.
- asthma control [ Time Frame: 1 year ] [ Designated as safety issue: No ]asthma control questionnaire
- Quality of life [ Time Frame: 1 year ] [ Designated as safety issue: No ]Asthma Quality of Life questionnaire for children
- cost-effectiveness [ Time Frame: 1 year ] [ Designated as safety issue: No ]incremental cost per exacerbation prevented
|Study Start Date:||November 2010|
|Study Completion Date:||March 2013|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Care as usual
Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01239238
|Maastricht University Hospital|
|Maastricht, Netherlands, 6202 AZ|
|Orbis Medical Centre|
|Principal Investigator:||Edward Dompeling, PhD MD||Maastricht UMC|